Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme

Nature Clinical Practice Oncology volume 5, pages 186–187 (2008)Cite this article

boxed-textVredenburgh JJ et al. (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722–4729

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Vredenburgh JJ et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253–1259

    Article  CAS  Google Scholar 

  2. Batchelor TT et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83–95

    Article  CAS  Google Scholar 

  3. Pope WB et al. (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66: 1258–1260

    Article  CAS  Google Scholar 

  4. Chen W et al. (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25: 4714–4721

    Article  CAS  Google Scholar 

  5. Rubenstein JL et al. (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2: 306–314

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. and B Purow is Assistant Professor of Clinical Neurology in the Department of Neurology, D Schiff is a Medical Neuro-Oncologist and Professor at the University of Virginia and Co-Director of the University of Virginia Neuro-Oncology Center, University of Virginia, Charlottesville, VA, USA.,

    David Schiff & Benjamin Purow

Authors
  1. David Schiff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Purow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Schiff.

Ethics declarations

Competing interests

David Schiff is a Consultant for and receives grant/research support from Genentech. Benjamin Purow declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiff, D., Purow, B. Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme. Nat Rev Clin Oncol 5, 186–187 (2008). https://doi.org/10.1038/ncponc1077

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1077

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing